Introduction: Targeted somatic genomic analysis (EGFR, anaplastic lymphoma receptor tyrosine kinase gene [ALK], and ROS1) and programmed death ligand 1 (PD-L1) tumor proportion score (TPS) determined by immunohistochemistry (IHC) are used for selection of first-line therapies in advanced lung cancer; however, the frequency of overlap of these biomarkers in routine clinical practice is poorly reported.
Introduction
The landscape for management of advanced NSCLCs has been revolutionized by the systematic identification of disease-specific characteristics that can be paired with precision systemic therapies. Testing for somatic mutations and rearrangements in EGFR, anaplastic lymphoma receptor tyrosine kinase gene (ALK), and ROS1 is now mandated as part of routine pretreatment evaluation in patients in whom advanced lung adenocarcinomas (ACs) have been diagnosed. When paired with the appropriate oral tyrosine kinase inhibitors (TKIs), patients in these molecularly defined subsets experience improved and durable outcomes, lesser toxicity, and better quality of life as compared with those receiving conventional platinum doublet chemotherapy. [1] [2] [3] More recently, the anti-programmed cell death 1 (PD-1) immune checkpoint inhibitor pembrolizumab has been approved by the U.S. States Food and Drug Administration (FDA) for first-line systemic therapy in advanced NSCLCs with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of at least 50% obtained by using the immunohistochemistry (IHC) clone 22C3. 4 The systemic therapy of choice for advanced NSCLCs of the AC histologic type without a classic driver oncogene aberration (i.e., EGFR/ALK/ROS1 negative) and with a PD-L1 TPS less than 50% remains a platinum doublet with or without bevacizumab in patients with adequate performance status and end-organ function. [1] [2] [3] However, the use of genomic and immune biomarkers in routine clinical care has generated a number of questions that have not been well answered by the large clinical trials published to date. What is the overlap of a PD-L1 TPS of at least 50% with the presence of classic targetable driver oncogene aberrations? How should one best select the appropriate first-line therapy on the basis of the tumor's biomarker profile? Can diagnostic NSCLC specimens obtained in routine clinical practice (i.e., small biopsy samples or cytologic cell blocks) be used for immune biomarker analysis? We postulate that classic driver oncogene aberrations and high PD-L1 expression do not often coexist, generating distinct subgroups of patients that may allow for optimal pairing of systemic therapies with disease characteristics. The current report depicts our real-world experience with the first consecutive 71 tumor-patient pairs analyzed for PD-L1 IHC by using the FDA-approved companion diagnostic, clone 22C3 pharmDx kit (Agilent Technologies, Santa Clara, CA). Our findings support the aforementioned postulation and indicate that a variety of routine clinical specimens may be acceptable for successful biomarker analysis.
Methods

Tumor and Data Collection
Patient and tumor pairs followed at Beth Israel Deaconess Medical Center with a diagnosis of lung cancer were recorded through an ongoing institutional review board-approved study, as previously reported. [5] [6] [7] Pathologic data, tumor genotype, PD-L1 TPS, and clinical characteristics were amassed from retrospective chart extraction. Data were collected and managed by using the REDCap electronic data capture held at Beth Israel Deaconess Medical Center. The cutoff for data collection was December 19, 2016.
Tumor Genomic Analyses
Tumor genotype was determined by analyzing EGFR (Sanger sequencing of exons 18-21), ALK (fluorescence in situ hybridization [FISH] break-apart probe), ROS1 (FISH break-apart probe), and KRAS (sequencing of codons 12-13) in tumor samples, as described previously. 5, 7 The aforementioned tests are bundled within the rapid tumor genotype panel outsourced to a commercial vendor by our hospital. More comprehensive genomic profiling was not directly evaluated within this analysis, but the methods were described previously.
5,7
Tumor PD-L1 Analysis PD-L1 IHC testing was performed at Integrated Oncology/LabCorp (New York, NY) using the PD-L1 clone 22C3 pharmDx kit and Dako Automated Link 48 platform (Dako, Carpenteria, CA). PD-L1 TPS was calculated as the percentage of at least 100 viable tumor cells with complete or partial membrane staining. The TPS interpretation was provided by the commercial vendor's pathologist.
Statistical Methods
Fisher's exact test was used to compare categorical variables. All p values reported are two sided, and tests were conducted at the 0.05 significance level.
Results
Baseline Clinical and Pathologic Characteristics in Tumors with or without a PD-L1 TPS of at Least 50%
Of the 71 lung AC tumor specimens analyzed, 21 (29.6%) had a PD-L1 TPS of at least 50% and 50 (70.4%) had a PD-L1 TPS less than 50% (Table 1 and Fig. 1A) . A PD-L1 TPS of at least 50% was seen significantly more frequently in lung ACs in smokers (former or current) than in never-smokers (p ¼ 0.0111) ( Table 1) . A PD-L1 TPS of at least 50% was not associated with patient sex, ethnicity, tumor stage, biopsy site, or biopsy type/ preparation (see Table 1 ).
Representative examples of PD-L1 IHC staining on different types of clinical specimens, including cytologic cell blocks from pleural fluid, cytologic cell blocks from lymph node aspirates, core needle biopsy samples, and surgical specimens, are displayed on Figure 1B .
PD-L1 TPS and Presence of Classic Driver Oncogene Aberrations
Of the 71 lung AC specimens analyzed, 13 had EGFR mutations, four had ALK rearrangements, and two had a ROS1 rearrangement (Table 1 and Fig. 2 ). Of these 19 tumors with EGFR mutations, ALK FISH positivity, or ROS1 FISH positivity, 18 had a PD-L1 TPS less than 50% (Table 1 and Fig. 2A ) as compared with only one tumor with a PD-L1 TPS of at least 50% (p ¼ 0.0073). The only tumor with a PD-L1 TPS of at least 50% and a classic driver oncogene aberration harbored an ALK rearrangement (Fig. 2B) . Other oncogene alterations are depicted on Figure 2 .
Overall Expression of PD-L1 TPS
PD-L1 TPS results provided by the commercial vendor are depicted in Table 1 . Notably, the most common PD-L1 TPS was 0% (n ¼ 30), followed by 1% to 24% (n ¼ 17), and a few tumors had an intermediate low expression PD-L1 TPS of 25% to 49% ( Table 1 ). The proportion of tumors with a PD-L1 TPS of at least 50% was divided into two quartiles: 50% to 74% (n ¼ 10) and 75% to 100% (n ¼ 11).
Discussion
To the best of our knowledge, our-single institution experience with targeted tumor genotyping in combination with PD-L1 IHC for characterization of NSCLCs in a noninvestigational setting is one of the first reports to evaluate the day-to-day applications of vetted biomarkers in this patient population. Until now, most published experience with PD-L1 characterization in NSCLC using the 22C3 pharmDx assay has been in large clinical studies of pembrolizumab and restricted to tissue obtained from formalin-fixed paraffin-embedded core or surgical biopsy samples; further, several of these studies excluded patients whose tumors harbored actionable driver oncogene mutations. 4, 8, 9 Our results are unique in demonstrating that the FDA-approved companion diagnostic for pembrolizumab-the PD-L1 clone 22C3 pharmDx kit-can generate actionable PD-L1 results in routine clinical specimens, including cytologic specimens from formalin-fixed paraffin-embedded cell blocks of fine-needle aspirates or effusion specimens (see Table 1 and Fig. 1B) . As many diagnostic specimens obtained for use in routine clinical practice may be of this variety (i.e., cytologic specimens as opposed to surgical resection specimens or core biopsy samples), our findings merit further validation to optimize biomarker assessment and therapeutic planning in the real-world setting.
Our finding that 29.6% of lung ACs had a PD-L1 TPS of at least 50% is consistent with prior reports using this same antibody platform and in larger cohorts; a PD-L1 TPS of at least 50% was reported in 24.9% to 30.2% of advanced NSCLCs in the phase I to III trials (KEYNOTE-001, KEYNOTE-024, and KEYNOTE-042) of pembrolizumab. 4, 8, 9 In one of the largest published screening cohorts for PD-L1 using the 22C3 pharmDx assay to date (i.e., that in the KEYNOTE-024 trial), the frequency of overlap between common driver oncogene aberrations (i.e., in EGFR or ALK) and a PD-L1 TPS of at least 50% was just 6% (30 of 500). 4 In our own singlecenter experience, high PD-L1 expression and abnormalities in EGFR, ALK, and ROS1 seldom overlapped: only one tumor that was ALK affected had a concurrent PD-L1 TPS of at least 50% (4.8% of overlap), and all specimens harboring abnormalities in EGFR or ROS1 had a PD-L1 TPS less than 50% (see Fig. 2 ). It is likely that the true frequency of overlap in larger cohorts will be on the order of less than 10%. Appropriately, the FDA label for pembrolizumab was written to highlight the fact that tumors with EGFR mutations or ALK rearrangements should not receive first-line pembrolizumab owing to the durable response rates that exceed 60% to 70% when patients with these tumors receive approved first-line EGFR-or ALK-directed TKIs [1] [2] [3] [10] [11] [12] ; these numbers far surpass the response rates published for conventional platinum doublet chemotherapy or immune checkpoint inhibitor monotherapy, even in tumors with the highest-level PD-L1 TPS of at least 50% (around 25%-30% and 40%-45%, respectively). 4 PD-L1 IHC scores obtained by using different epitopes and measurement methods are also somewhat predictive of response to the PD-1 inhibitor nivolumab 13 and the PD-L1 inhibitor atezolizumab in the management of advanced lung ACs.
14 Notably, these other PD-L1 IHC platforms have yet to receive companion diagnostic designation by the FDA. The harmonization of PD-L1 testing remains a serious unmet need, as there are notable variations in the antibodies and staining platforms used, definitions of positivity, and assay methodologies (i.e., assessment of tumor cells versus tumor-infiltrating immune cells). To the latter end, the Blueprint PD-L1 IHC Assay Comparison Project provided initial results demonstrating that the extent and intensity of PD-L1-stained tumors were relatively comparable between the 22C3, 28-8, and SP263 IHC assays but not the SP142 IHC assay. 15 In summary, our real-world experience with the use of genomic and immunologic biomarkers in routine advanced lung AC samples demonstrates that multiple types of diagnostic clinical tissue samples can be successfully utilized, that the frequency of a PD-L1 TPS of at least 50% obtained by using the 22C3 pharmDx assay is approximately 30% in this population, and that a PD-L1 TPS of at least 50% seldom overlaps with the presence of actionable driver oncogenes (i.e., EGFR, ALK, and ROS1).
On the basis of this evolving paradigm of disease characterization, we can now define three distinct subsets of patients with advanced lung AC ( Supplementary Fig. 1A ) and with highly relevant therapeutic implications ( Supplementary Fig. 1B ): (1) EGFR/ALK/ROS1 affected (w20% of cases according to large multi-institutional cohorts 1 ), (2) PD-L1-enriched (TPS 50%) in approximately 30% of cases, and (3) biomarker negative (i.e., EGFR/ALK/ROS1/PD-L1-negative) in approximately 50% of cases.
Decades after the initial studies of cytotoxic chemotherapy first demonstrated benefit in physically fit patients with molecularly undefined tumors, nearly half of all patients with advanced lung AC now have the opportunity to receive a specific therapy that may afford brisk and/or durable response and with lesser toxicity than with conventional platinum doublet chemotherapy. [1] [2] [3] [10] [11] [12] Further translational research will help define additional predictive biomarkers in NSCLC that will help further improve outcomes for our patientsparticularly for the remaining half of patients for whom no precision first-line therapy is available. 
